ABSTRACT
Introduction Genetic testing for hypertrophic cardiomyopathy (HCM) is considered a key aspect of management. Communication of genetic test results to the proband and their family members, can be a barrier to effective uptake. We hypothesized that a communication aid would facilitate effective communication, and sought to evaluate knowledge and communication of HCM risk to at-risk relatives.
Methods This was a prospective randomized controlled trial. Consecutive HCM patients attending a specialized clinic, who agreed to participate, were randomized to the intervention or current clinical practice. The intervention consisted of a genetic counselorled appointment, separate to their clinical cardiology review, and guided by a communication booklet which could be written in and taken home. Current clinical practice was defined as the return of the genetic result by a genetic counselor and cardiologist, often as part of a clinical cardiology review. The primary outcome was the ability and confidence of the individual to communicate genetic results to at-risk relatives.
Results The a priori outcome of improved communication amongst HCM families did not show statistically significant differences between the control and intervention group, though the majority of probands in the intervention group achieved fair communication (n=13/22) and had higher genetic knowledge scores than those in the control group (7 ± 3 versus 6 ± 3). A total of 29% of at-risk relatives were not informed of a genetic result in their family.
Conclusion Communication amongst HCM families remains challenging, with nearly a third of at-risk relatives not informed of a genetic result. We show a significant gap in the current approach to supporting family communication about genetics.
Australian New Zealand Clinical Trials Registry: ACTRN12617000706370
What is known about this topic Communication between family members regarding genetic testing can be a barrier to effective uptake.
What this paper adds to the topic Communication is a challenge in HCM families, with nearly a third of at-risk relatives not informed of a genetic result. There is a significant gap in the current approaches to supporting family communication about genetics.
Competing Interest Statement
JI receives research grant support from Bristol Myers Squibb. All other authors report no competing interests.
Clinical Trial
ACTRN12617000706370
Clinical Protocols
https://bmjopen.bmj.com/content/9/1/e026627
Funding Statement
LY is a recipient of a co-funded National Heart Foundation of Australia / National Health and Medical Research Council (NHMRC) PhD scholarship (#102568/#191351). CS is the recipient of a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (#1154992). JI is the recipient of an NHMRC Career Development Fellowship (#1162929).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants provided written informed consent. Ethical approval was granted by the Sydney Local Health District Human Research Ethics Review Committee (X16-0030).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: JI receives research grant support from Bristol Myers Squibb. All other authors report no competing interests.
Ethics: Participants provided written informed consent. Ethical approval was granted by the Sydney Local Health District Human Research Ethics Review Committee (X16-0030).
Trial registration: The trial was registered with the Australian New Zealand Clinical Trials Registry: ACTRN12617000706370.
Data Availability
All data produced in the present study are available upon reasonable request to the authors and in accordance with ethical approvals.
Data Availability
All data produced in the present study are available upon reasonable request to the authors and in accordance with ethical approvals.
